glp-1 fda approval 💊New pill gets approval, and has fewer restrictions on how it's used💊 FDA Approves Oral Semaglutide as

A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found that exogenous IGF-1 administration produced detectable anabolic effects within 72 hours

Patients notice that they feel less hungry, they get full faster, and they often lose weight

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study

Traditional blockbusters (biologics for oncology or immunology) still lead in aggregate revenue

Important safety considerations include: Cardiovascular history : Patients with established cardiovascular disease require careful assessment, though recent evidence suggests GLP-1 receptor agonists may offer cardiovascular benefits Medication interactions : No clinically significant interactions are expected between GLP-1 receptor agonists and statins or other lipid-lowering medications, though delayed gastric emptying could theoretically affect absorption of oral medications Pancreatitis risk : Whilst rare, acute pancreatitis has been reported with GLP-1 receptor agonists